Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Aripiprazole in Children With Autism: A Pilot Study

This study has been completed.
Information provided by (Responsible Party):
Drexel University ( Drexel University College of Medicine ) Identifier:
First received: September 13, 2005
Last updated: August 13, 2014
Last verified: August 2014

This is a 6-week open pilot study of aripiprazole for the treatment of adolescents, aged 12 to 18 years, diagnosed with autism.

Children who qualify for the study will be treated with aripiprazole for 6 weeks.

Treatment is provided at no cost.

Condition Intervention Phase
Drug: Aripiprazole
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Aripiprazole in Children With Autism: A Pilot Study

Resource links provided by NLM:

Further study details as provided by Drexel University:

Primary Outcome Measures:
  • Clinical Global Impressions [ Time Frame: Week 6 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Children's Psychiatric Rating Scale [ Time Frame: Baseline, Week 6 ] [ Designated as safety issue: No ]

Enrollment: 11
Study Start Date: February 2004
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1 Open Label
Open Label Aripiprazole
Drug: Aripiprazole
Aripiprazole 5 mg to 30mg, individually titrated
Other Name: Abilify

  Show Detailed Description


Ages Eligible for Study:   12 Years to 18 Years   (Child, Adult)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of autism (DSM-IV) made by a boarded child and adolescent psychiatrist.
  • Males and females.
  • Aged 12 to 18 years.
  • Clinical judgment that medication treatment for autism is indicated.

Exclusion Criteria:

  • Major medical problems including cardiac, liver, endocrine, or renal diseases.
  • Uncontrolled seizures.
  • Baseline QTC greater than 425 msec.
  • Concomitant treatment with psychotropic medication.
  • History of prior exposure to aripiprazole.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00208533

United States, Pennsylvania
Drexel University College of Medicine at Friends Hospital
Philadelphia, Pennsylvania, United States, 19124
Sponsors and Collaborators
Drexel University College of Medicine
Principal Investigator: Richard P Malone, MD Drexel University College of Medicine
  More Information

Responsible Party: Drexel University College of Medicine Identifier: NCT00208533     History of Changes
Other Study ID Numbers: 02841 
Study First Received: September 13, 2005
Last Updated: August 13, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Drexel University:
Pervasive developmental disorder
Antipsychotic medication

Additional relevant MeSH terms:
Autistic Disorder
Child Development Disorders, Pervasive
Neurodevelopmental Disorders
Mental Disorders
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs processed this record on January 17, 2017